BDNF Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease
Archives of Clinical Neuropsychology · 2024
DOI: 10.1093/arclin/acae014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Neuropsychology, 2024. Verfasst von Diny Thomson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC 3168, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Brain-Derived Neurotrophic Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Drug Discovery Foundation, NIA NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Objective
Allelic variation in the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has been shown to moderate rates of cognitive decline in preclinical sporadic Alzheimer’s disease (AD; i.e., Aβ + older adults), and pre-symptomatic autosomal dominant Alzheimer’s disease (ADAD). In ADAD, Met66 was also associated with greater increases in CSF levels of total-tau (t-tau) and phosphorylated tau (p-tau181). This study sought to determine the extent to which BDNF Val66Met is associated with changes in episodic memory and CSF t-tau and p-tau181 in Aβ + older adults in early-stage sporadic AD.
Method
Aβ + Met66 carriers (n = 94) and Val66 homozygotes (n = 192) enrolled in the Alzheimer’s Disease Neuroimaging Initiative who did not meet criteria for AD dementia, and with at least one follow-up neuropsychological and CSF assessment, were included. A series of linear mixed models were conducted to investigate changes in each outcome over an average of 2.8 years, covarying for CSF Aβ42, APOE ε4 status, sex, age, baseline diagnosis, and years of education.
Results
Aβ + Met66 carriers demonstrated significantly faster memory decline (d = 0.33) and significantly greater increases in CSF t-tau (d = 0.30) and p-tau181 (d = 0.29) compared to Val66 homozygotes, despite showing equivalent changes in CSF Aβ42.
Conclusions
These findings suggest that reduced neurotrophic support, which is associated with Met66 carriage, may increase vulnerability to Aβ-related tau hyperphosphorylation, neuronal dysfunction, and cognitive decline even prior to the emergence of dementia. Additionally, these findings highlight the need for neuropsychological and clinicopathological models of AD to account for neurotrophic factors and the genes which moderate their expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC 3168, Australia.
- Cogstate Ltd, Melbourne, VIC 3000, Australia.
ORCID-Profile: Diny Thomson, Yen Ying Lim
Förderung
- Alzheimer's Drug Discovery Foundation
- NIA NIH HHS
- Alzheimer's Association
- NIBIB NIH HHS
- Neurotrack Technologies
- CIHR
- Alzheimer's Disease Neuroimaging Initiative
- Piramal Imaging
Zitieren
APA
Thomson, D., Rosenich, E., Maruff, P., Lim, Y. Y., & Alzheimer’s Disease Neuroimaging Initiative (2024). BDNF Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease. Archives of Clinical Neuropsychology. https://doi.org/10.1093/arclin/acae014
Vancouver
Thomson D, Rosenich E, Maruff P, Lim YY, Alzheimer’s Disease Neuroimaging Initiative. BDNF Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease. Archives of Clinical Neuropsychology. 2024. doi:10.1093/arclin/acae014
BibTeX
@article{Thomson2024,
author = {Thomson, Diny and Rosenich, Emily and Maruff, Paul and Lim, Yen Ying and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative},
title = {BDNF Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease},
journal = {Archives of Clinical Neuropsychology},
year = {2024},
doi = {10.1093/arclin/acae014}
}
EUVIMED